CNBC
19 Dec 2025, 19:34 UTC · 38w ago
Verdict
Headline leans bearish. We score BMY −0.40 across five claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Major drugmakers including Merck, Bristol Myers Squibb, and Novartis agreed to lower U.S. drug prices and align them with cheaper international 'most favored nation' pricing.
So whatSignificant price reductions on high-volume medications directly compress profit margins and top-line revenue for the pharmaceutical sector.
More negative than 98% of claims this week
Bristol Myers Squibb will provide its blockbuster blood thinner, Eliquis, to Medicaid for free.
Continue reading
5 related stories
More negative than 76% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Several companies, including Merck and Sanofi, will offer deep discounts (up to 70%) on popular medications via the new direct-to-consumer platform, TrumpRx.
So whatDirect-to-consumer discounting erodes the traditional pricing power and rebate structures used by pharmaceutical companies.
More negative than 86% of claims this week
Participating drug companies will receive a three-year grace period exempting them from planned pharmaceutical-specific tariffs, provided they invest in U.S. manufacturing.
More positive than 77% of claims this week
Johnson & Johnson, AbbVie, and Regeneron are among the few large pharma companies that have not yet signed these pricing deals.
More negative than 66% of claims this week
Which stocks this story touches
More negative than 76% of ticker scores this week
Agreeing to provide its blockbuster drug Eliquis for free to Medicaid.
More negative than 73% of ticker scores this week
Agreeing to offer discounts of nearly 70% on certain medications.
More negative than 69% of ticker scores this week
Previously agreed to sell drugs directly to patients at a discount.
More negative than 69% of ticker scores this week
Agreeing to voluntarily sell medications for less to avoid pharmaceutical tariffs.
More negative than 69% of ticker scores this week
Previously agreed to sell drugs directly to patients at a discount.
More negative than 69% of ticker scores this week
Agreeing to lower drug prices and offer significant discounts on diabetes medications.
More negative than 69% of ticker scores this week
Previously agreed to sell drugs directly to patients at a discount.
More negative than 69% of ticker scores this week
Agreeing to voluntarily lower drug prices to avoid planned tariffs.
More negative than 69% of ticker scores this week
Previously agreed to sell drugs directly to patients at a discount.
More negative than 69% of ticker scores this week
Agreeing to voluntarily lower drug prices to avoid planned tariffs.
More negative than 69% of ticker scores this week
Agreeing to lower prices and expand direct-to-patient discounts for migraine and autoimmune treatments.
More negative than 69% of ticker scores this week
Agreeing to lower prices and provide discounted access to its hepatitis C treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
6h ago
+20.3%
Price is moving against the score
$64.13 vs $53.33 close before publication (Dec 18) · not market-adjusted
BMY chart →
